Analyst Research Report Snapshot

Title:

ZEALAND PHARMA - LIXI PROSPECTS SEE SAW

Price:

$10.00

Provider:

Edison Investment Research

Date:

18 Feb 2013

Pages:

2

Type:

AcrobatPDF

Companies referenced:

ZELA.CO

Available for Immediate Download
Summary:

A surprise regulatory setback for Novo Nordisk’s Tresiba has suddenly improved the prospects for Zealand’s key partnered programme just days after they were dashed. Thus, the setback that came with the disclosure by Sanofi of a delay in the development of the Fix-Flex combination product has been somewhat offset by the delay to Novo’s competing insulin/GLP-1 agonist combination, as a result of the FDA’s rejection of Tresiba. While uncertainty remains about the development timelines for Sanofi’s combination product, the shape of the future diabetes landscape has now shifted back in its (and thus Zealand’s) direction. Furthermore, after a 20% fall, Zealand’s share price has yet to reflect this new situation.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.